Genomic Testing Cooperative to Present at the AACR 2023 Meeting Demonstrating Reliability of Targeted Transcriptomic Profiling in Predicting Levels of HER2, ER, PD-L1 and Other Immunohistochemistry-based Biomarkers when Combined with AI

IRVINE, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting data at the 2023 American Association of Cancer Research (AACR) Annual Meeting demonstrating that its targeted transcriptomic profiling correlates with immunohistochemistry (IHC)-based testing. Targeted transcriptomic data generated in GTC’s routine genomic profiling of tumors is used to quantify various IHC-based biomarkers including HER2, PD-L1, estrogen Receptor (ER), androgen receptor and others. GTC studies demonstrate that RNA sequencing of clinically relevant genes using next generation sequencing (NGS) provides reliable quantitative data that can be interpreted objectively. This data when used in artificial intelligence (AI) algorithms can predict levels of PD-L1 not only in tumor cells, but also in inflammatory cells. The current data suggests that transcriptomic data can replace the need for some IHC test and potentially may better address clinically relevant questions such as determining low HER2 level and others.

“We believe that transcriptomic profiling is essential in today’s molecular profiling of cancers. Targeted transcriptomic allows us to focus on the clinically relevant genes and provides better dynamic range,” stated Dr. Maher Albitar, founder, chief medical officer, and chief executive officer of GTC. “The generated data when used in AI algorithms allows us to develop new clinical applications and answer clinical questions that few years ago, we thought not possible to answer in routine clinical testing. GTC is leading in this field,” added Dr. Albitar.

This data will be presented in the following three posters:

- Predicting PD-L1 status in solid tumors using transcriptomic data and artificial intelligence algorithms: Session Date and Time: Tuesday Apr 18, 2023 9:00 AM - 12:30 PM (4337 / 12)

- Real-world transcriptomic biomarkers as replacement for immunohistochemistry and FISH studies in breast cancer: Session Date and Time: Sunday Apr 16, 2023 1:30 PM - 5:00 PM (967 / 18)

- The molecular landscape of premenopausal versus postmenopausal breast cancer in patients without inherited predisposition mutations: Session Date and Time: Sunday Apr 16, 2023 1:30 PM - 5:00 PM (929 / 12)

Visit GTC booth #1775 at AACR for more detail and highlights on this work and on how to become a member of the Co-Op.

About Genomic Testing Cooperative, LCA

Genomic Testing Cooperative (GTC) is a privately-owned molecular testing company located in Irvine, CA. The company operates based on a cooperative (co-op) business model. Members of the co-op hold type A shares with voting rights. The company offers its patron members a full suite of comprehensive genomic profiling based mainly on next generation sequencing. Molecular alterations are identified based on rigorous testing with the aid of specially developed algorithms to increase accuracy and efficiency. The clinical relevance of the detected alterations is pulled from numerous databases using internally developed software. Relevance of findings to diagnosis, prognosis, selecting therapy, and predicting outcome are reported to members. The co-op model allows GTC to make the testing and information platform available to members at a lower cost because of a lower overhead. For more information, please visit https://genomictestingcooperative.com/.

Forward Looking Statements

All of the statements, expectations and assumptions contained in this press release are forward-looking statements. Such forward-looking statements are based on the GTC management’s current expectations and includes statements regarding the value of comprehensive genomic profiling, RNA profiling, DNA profiling, algorithms, therapy, the ability of testing to provide clinically useful information. All information in this press release is as of the date of the release, and GTC undertakes no duty to update this information unless required by law.